Allurion Technologies Announced Data From Over 19,000 Patients Between 2018-2023 That Used Its Program Showing An Average Loss Of 12.2% Of Total Body Weight

Benzinga11/04 21:14

Allurion Presents The Second Abstract Reports On Outcomes Of The Allurion Program For 27 Patients Previously Treated With Liraglutide Who Did Not Respond To Their GLP-1 Treatment. 55% Had No Weight Loss And 45% Had Weight Loss Of Less Than 5% With...

Benzinga11/04 21:12

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society's Annual Conference

Businesswire11/04 21:10

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Businesswire10/30 20:30

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Business Wire10/23 20:00

Coverage Initiation And Bullish Price Target Sends Micro Cap Flying

Yolowire10/02 22:59